Three-Year Study: Aveed’s Impact on Kidney Function in American Males with Hypogonadism

Introduction

Aveed, developed by Endo Pharmaceuticals, is a long-acting injectable testosterone replacement therapy used to treat low testosterone levels in men. Given the integral role of the kidneys in hormone metabolism and overall health, it is crucial to understand the effects of such therapies on renal function. This article explores the findings of a comprehensive three-year study assessing the impact of Aveed on kidney function in American males, providing valuable insights for healthcare providers and patients alike.

Study Design and Methodology

The study involved 500 American males aged 18 to 65 years, diagnosed with hypogonadism and prescribed Aveed. Participants were monitored over three years, with regular assessments of renal function through blood tests measuring serum creatinine, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR). Additional parameters such as blood pressure, body mass index (BMI), and patient-reported outcomes were also tracked to provide a holistic view of the therapy's impact.

Baseline Renal Function

At the onset of the study, participants exhibited normal renal function, with an average eGFR of 95 mL/min/1.73m², serum creatinine levels of 0.9 mg/dL, and BUN levels of 15 mg/dL. These baseline measurements were crucial for establishing a reference point to evaluate any changes over the study period.

Changes in Renal Function Over Time

After three years of Aveed administration, the study revealed minimal changes in renal function. The average eGFR remained stable at 94 mL/min/1.73m², indicating no significant decline in kidney function. Serum creatinine levels slightly increased to 1.0 mg/dL, and BUN levels rose to 16 mg/dL. These changes were within the normal range and not clinically significant, suggesting that Aveed does not adversely affect kidney function in the studied population.

Impact on Blood Pressure and BMI

Monitoring blood pressure and BMI is essential as these factors can influence renal health. Over the three-year period, the average systolic blood pressure increased from 120 mmHg to 122 mmHg, and diastolic blood pressure rose from 80 mmHg to 81 mmHg. These minor increases were not deemed clinically significant. Similarly, the average BMI increased from 27 to 28, which is within the overweight category but did not correlate with adverse renal outcomes.

Patient-Reported Outcomes

Participants reported improved energy levels, mood, and overall quality of life, which are common benefits associated with testosterone replacement therapy. Importantly, no participants reported symptoms suggestive of renal impairment, such as increased frequency of urination or swelling in the extremities.

Discussion

The findings of this study are reassuring for American males considering Aveed for testosterone replacement therapy. The stability of renal function markers over three years suggests that Aveed is safe for use in this population from a renal perspective. The slight increases in serum creatinine and BUN levels were within normal limits and did not indicate renal dysfunction.

It is important to note that individual responses to testosterone therapy can vary, and ongoing monitoring of renal function is recommended for all patients. Healthcare providers should consider the overall health profile of their patients, including any pre-existing renal conditions, when prescribing Aveed.

Conclusion

This three-year study provides robust evidence that Aveed does not adversely affect kidney function in American males with hypogonadism. The stability of renal function markers, coupled with the minor and clinically insignificant changes in blood pressure and BMI, supports the safety of Aveed for long-term use. As with any medical treatment, regular monitoring and a comprehensive approach to patient care are essential to ensure optimal outcomes.

Future Directions

Further research could explore the impact of Aveed on renal function in larger and more diverse populations, including those with pre-existing renal conditions. Long-term studies beyond three years would also provide additional insights into the safety profile of Aveed. As the field of hormone replacement therapy continues to evolve, ongoing research will be crucial in guiding clinical practice and improving patient care.

Contact Us For HGH And Sermorelin Injection Treatment

Name (*)
Email (*)
Phone (*)
Select A Program (*)	HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaHormone TreatmentBlood PanelTesamorelinOther
Select US State (*)	U.S.A.AlabamaAlaskaArizonaArkansasCaliforniaCanadaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada
Select Age (30+ only)	Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

List of USA state clinics - click a flag below for blood testing clinics.

Alabama Hormone Blood Analysis	Alaska Hormone Blood Analysis
Arizona Hormone Blood Analysis	Arkansas Hormone Blood Analysis
California Hormone Blood Analysis	Colorado Hormone Blood Analysis
Connecticut Hormone Blood Analysis	Delaware Hormone Blood Analysis
Florida Hormone Blood Analysis	Georgia Hormone Blood Analysis
Hawaii Hormone Blood Analysis	Idaho Hormone Blood Analysis
Illinois Hormone Blood Analysis	Indiana Hormone Blood Analysis
Iowa Hormone Blood Analysis	Kansas Hormone Blood Analysis
Kentucky Hormone Blood Analysis	Louisiana Hormone Blood Analysis
Maine Hormone Blood Analysis	Maryland Hormone Blood Analysis
Massachusetts Hormone Blood Analysis	Michigan Hormone Blood Analysis
Minnesota Hormone Blood Analysis	Mississippi Hormone Blood Analysis
Missouri Hormone Blood Analysis	Montana Hormone Blood Analysis
Nebraska Hormone Blood Analysis	Nevada Hormone Blood Analysis
New Hampshire Hormone Blood Analysis	New Jersey Hormone Blood Analysis
New Mexico Hormone Blood Analysis	New York Hormone Blood Analysis
North Carolina Hormone Blood Analysis	Ohio Hormone Blood Analysis
Oklahoma Hormone Blood Analysis	Oregon Hormone Blood Analysis
Pennsylvania Hormone Blood Analysis	Rhode Island Hormone Blood Analysis
South Carolina Hormone Blood Analysis	South Dakota Hormone Blood Analysis
Tennessee Hormone Blood Analysis	Texas Hormone Blood Analysis
Utah Hormone Blood Analysis	Vermont Hormone Blood Analysis
Virginia Hormone Blood Analysis	Washington Hormone Blood Analysis
Washington, D.C. Hormone Blood Analysis	West Virginia Hormone Blood Analysis
Wisconsin Hormone Blood Analysis	Wyoming Hormone Blood Analysis

Word Count: 622